Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
N = 15
- Population
- Patients with APL at relapse after ATRA-induced and chemotherapy-maintained complete remission
- Design
- Treatment series; phase not stated in the abstract. As2O3 10 mg/d intravenously: 10 patients received As2O3 alone, five received As2O3 with low-dose chemotherapeutic drugs or ATRA.
- Arms
- Arsenic trioxide (experimental, n = 15): As2O3 10 mg/d intravenously (alone in 10 patients; with low-dose chemotherapy or ATRA in 5)
- People
- Shen ZX
Show the numbers
| Endpoint | Analysis | Arsenic trioxide | Control | Effect |
|---|---|---|---|---|
| Complete remission rate10 patients treated with As2O3 alone | primaryShen 1997 | 90% | — | 9 of 10 patients. The abstract also reports clinical complete remission in the remaining five patients, who received As2O3 combined with low-dose chemotherapy or ATRA; no combined rate is computed here. No bone marrow depression and only limited side effects were reported. |
| Endpoint | Analysis | Arsenic trioxide | Control | Effect |
|---|---|---|---|---|
| Complete remission rate10 patients treated with As2O3 alone | primaryShen 1997 | 90% | — | 9 of 10 patients. The abstract also reports clinical complete remission in the remaining five patients, who received As2O3 combined with low-dose chemotherapy or ATRA; no combined rate is computed here. No bone marrow depression and only limited side effects were reported. |
Appears in
Sources
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354-60.